PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Center for the AIDS Programme of Research in South Africa, Durban, South Africa.\', \'Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA.\', \'Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.\', \'Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.\', \'Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.\', \'Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA. Electronic address: aiafrate@partners.org.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S1535-6108(21)00614-010.1016/j.ccell.2021.12.002
?:hasPublicationType
?:journal
  • Cancer cell
is ?:pmid of
?:pmid
?:pmid
  • 34990570
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 12.7
?:rankingScore_hIndex
  • 284
is ?:relation_isRelatedTo_publication of
?:title
  • Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all